CNSP
What one share of CNS Pharmaceuticals holds
Pharmaceutical Preparations
Together, these therapeutic areas represent hundreds of billions of dollars in annual global pharmaceutical
CNS Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$7.66 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$6.16 |
| Cash and investments | $13.67 |
| Debt | $0.21 |
| Book value | $12.45 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$853.68 | $1.62 | −$662.15 | — | $877.01 |
| 2021 | — | −$825.05 | $0.33 | −$770.91 | — | $324.70 |
| 2022 | — | −$560.83 | $0.16 | −$387.82 | — | $251.43 |
| 2024 | — | −$466.89 | $0.13 | −$537.90 | — | — |
| 2025 | — | −$35.75 | $0.04 | −$31.19 | — | $7.15 |